Amit K. Verma, M.B.B.S.

https://einsteinmed.edu/labs/amit-verma/

Targeting signal transduction in hematologic malignancies: 
Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways. 

Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms: 
We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML. 

Epigenomic analysis of tumors:
We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.

Clinical studies in Myelodysplastic syndromes:
We have a “center of excellence” clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.

1. Elevated clonal hematopoiesis in 9/11 first responders has distinct age-related patterns and relies on IL1RAP for clonal expansion..
   Verma D, Zeig-Owens R, Goldfarb DG, Kravets L, Pradhan K, Rockwell B, Sahu S, Kelly S, Giricz O, Jasra S, Zou Y, Prophete C, Torres LS, Aluri S, Chakraborty S, Kumari R, Gordon-Mitchell S, Wang J, Silver AJ, South TM, Olmstead SD, Hall CB, Sidoli S, Bender R, Landgren O, Greenberger LM, Wickrema A, Madireddy A, Shastri A, Pietras EM, LaFave LM, Nolan A, Cohen MD, Savona MR, Steidl U, Prezant DJ, Verma A. Cancer Discov. 2025 Oct 1. PMID: 41031953.
2. Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.
   Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, Verma A. J Clin Invest. 2025 May 27. PMID: 40424086.
3. Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.
   Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* Verma A,* Salomonis N.* Sci Transl Med. 2025 May 7. PMID: 40333990. *Co Corresponding
4.   Nonoperative Management of Mismatch Repair-Deficient Tumors. Jakubowski CD, Verma A, Gartrell BA.N Engl J Med. 2025 Sep 25;393(12):1241-1242. PMID: 40991908.
5. Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism . Harris B, Singh DK, Truong B, Rhodes M, Price R, Shinton S, Verma M, Aylward B,  Fahl SP, Sprinkle SR, Aminov S, Wang M, Zhang Y, Perrigoue J, Kessel R, Peri S, West J, Giricz O, Boultwood J, Pellagatti A, Ramesh KH, Montagna C, Pradhan K, Tyner JW, Kennedy BK, Holinstat M, Steidl U, Sykes S*, Verma A*, Wiest DL.* (* Equal contribution) Cell Rep. 2025 Dec 12;44(12):116688. PMID: 41389200.
6. A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.
   Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, Verma A.
   Blood. 2024 Sep 24.PMID: 39316768
7. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.
   DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A*, Konopleva M*.
   Nat Cancer. 2024 Sep 19. PMID: 39300320
   *CoCorresponding
8. Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.
   Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, Verma A, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.
   Nat Genet. 2024 Sep 18. PMID: 39294495
9. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.
   Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, Verma A, Neugebauer KM, Pillai MM. Mol Cell. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065
10. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency .  Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. JCI. 2024 Feb 20 PMID: 38376944.
11. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. Thakkar A, Pradhan K, Duva B, Carreño JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, Verma A*, Halmos B*. Elife. 2023, Mar 28;12:e83694. PMID: 36975207.
12. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.  Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. PMID: 37341641.
13. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations . Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, Verma A*. Elife. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103.
14. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster.   Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, Verma A. Nat Med. 2022 Mar 7. PMID: 35256801.
15. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, Verma A. Cancer Cell. 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706
16. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, Verma A*, Halmos B*. *Co-Corresponding Cancer Cell. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.
17. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis . Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Leukemia. 2022 Feb 26. PMID: 35220402.
18. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells . Pinho S, Wei Q, Maryanovich M, Zhang D, Balandrán JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK, Verma A, Frenette PS. Nat Cell Biol. 2022 Feb 24. PMID: 35210567.
19. The Genomics of Colorectal Cancer in Populations with African and European Ancestry .  Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, Verma A, Greally JM, Raj SM, Goel S, Ali SM. Cancer Discov. 2022 Feb 17: PMID: 35176763.
20. Methylation of dual-specificity phosphatase 4 controls cell differentiation.   Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, Verma A*, Luo M*, Zhao X*. Cell Rep. 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.
21. Seroconversion rates following COVID-19 vaccination among patients with cancer . Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A*, Halmos B*.  Cancer Cell. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding.
22. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism . Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, Verma A, Steidl U. Cancer Cell. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.
23. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production . Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, Verma A. Dev Cell, 2021, Mar 8;56(5):627-640. PMID: 33651979.
24. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population . Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Verma A, Braunschweig I, Goldfinger M. Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. PMID: 33846558.
25. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy . Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B. Nature Cancer, 2021, 2: 392–399.
26. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System . Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, Verma A*. Cancer Discov. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.
27. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin . List AF, Sun Z, Verma A*, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS. JCO, 2021, Jan 13: PMID: 33439748 *Corresponding.
28. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. J Clin Invest. 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337.
29. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes . Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. N Engl J Med. 2020 Jan 9;382(2):140-151. PMID: 31914241.
30. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts . Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*, Verma A*. Elife, Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852
31. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes . Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Clin Cancer Res. 2019 Sep 3. PMID: 31481511
32. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies . Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D*.   Nature Cell Bio. 2019 May;21(5):640-650 * Equal Contribution PMID: 31011167.
33. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis . Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,* Wickrema A*.  Cancer Discovery. 2019 Jun;9(6):778-795 * Equal Contribution PMID: 30944118.
34. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts . Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*, Verma A*. Elife. Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852.
35. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes . Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Clin Cancer Res. 2019 Sep 3. PMID: 31481511.
36. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level . Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A*, Steidl U*. Nature Medicine. 2019, Jan;25(1):103-110 * Equal Contribution PMID: 30510255.
37. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.  Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B. Verma, A. J Clin Invest. 2018 Sep 25. PMID: 30252677.
38. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies . Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A*, Ye BH*, Janakiram M.* Blood. 2018 Aug 13. PMID: 30104217 * Equal Contribution
39. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster . Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A*, Prezant DJ*.   JAMA Onc., 2018 Jun 1;4(6):821-827. PMID: 29710195  * Equal Contribution
40. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.  Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Sci Transl Med. 2018 Sep 12;10(458). PMID: 30209246.
41. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.   Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.  JCI Insight. 2018 Jul 25;3(14). PMID: 30046005.
42. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.  Sci Transl Med. 2018, Apr 11;10(436). PMID: 29643228
43. IL1RAP potentiates multiple oncogenic signaling pathways in AML.   Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.   J Exp Med. 2018 Jun 4;215(6):1709-1727 PMID: 29773641.
44. Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways.   Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A.   Genome Res. 2017, Oct 6. PMID: 28986391.
45. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation . Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,  Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.  Cancer Research. Jul, 2017, PMID: 28684528.
46. Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia .  Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Cancer Cell. 2017 Oct 9.PMID: 29017059.
47. Pharmacological inhibition of the transcription factor PU.1 in leukemia .  Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U. J Clin Invest. 2017 Oct 30, PMID: 29083320.
48. Efficacy of ALK5 Inhibition in Myelofibrosis.   Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, Verma A*, Epling-Burnette PK* (*Co-Corresponding), “Efficacy of ALK5 Inhibition in Myelofibrosis.” JCI Insight. 2017 April 6, PMID: 28405618.
49. Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.  Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A*, Susztak K* (*Co-Corresponding). JBC. 2017, Jan 20, PMID: 2790905.
50. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia . Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,  Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A. Cancer Res. 2016 Jun 10. PMID: 27287719.
51. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort . Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,  Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I, Verma A. Leukemia 2016 Apr 29. PMID: 27125205.
52. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG.  Nat Commun. 2016 Feb 22;7:10739. PMID: 26898884.
53. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.Lancet Haematol. 2015 Oct;2(10):e417-26. PMID: 26686043.
54. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes . Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*, Verma A*, Wickrema A*. (*Co-Corresponding). PNAS 2015; Nov 17;112(46): PMID: 26578796.
55. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia . Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. Nature Chem Biol. 2015 Oct 5. PMID: 26436839.
56. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome .  Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U. Blood. 2015 Jul 13. PMID: 26170031.
57. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion .  Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Br J Haematol. 2015 Jun 24. PMID: 26105212
58. Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.  Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E. Mol Cell. 2015 Jun 3. PMID: 26051178.
59. Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells .  Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC. Mol Cell Biol. 2015 May 26. PMID: 26012550.
60. Central role of ULK1 in type I interferon signaling.  Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC. Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232.
61. TET1 is a tumor suppressor of hematopoietic malignancy.  Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I.  Nat Immunol. 2015 Apr 13. PMID: 25867473.
62. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*,   *co-corresponding authors. Blood. 2015, Mar 25. PMID: 25810490. 
63. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.  Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J.  Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665. 
64. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.  Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, Blood. 2015 Jan 8. PMID: 25573988.
65. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia . Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U. Nature Medicine. 2015 Oct;21(10):1172-81. PMID: 26343801.
66. Targeting chemokine pathways in esophageal adenocarcinoma . Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A. Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576.
    
67. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival . Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A. Clin Cancer Res. 2014 Jun 10. PMID: 24916699.
68. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma . Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA. Cell Rep. 2014 May 14. PMID: 24835990.
69. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes . Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P. Blood. 2014 Jun 2. PMID: 24891322.
70. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.   Tamari R,  Schinke C, Bhagat T, Roth M, Braunschweig I,  Will B,  Steidl U, Verma A. Leuk Lymphoma. 2014 Dec;55(12):2901-6.PMID: 24650011.
71. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia . Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U, *Co-Corresponding.  Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588.
72. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.  Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S. Oncogene. 2014 Mar 31 PMID: 24681958.
73. Recurrent genetic defects on chromosome 7q in myeloid neoplasms.  Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.” Leukemia. 2014 Jan 16. PMID: 24429498.
74. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis . Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA.  Cell Reports. 2013 Dec 24 PMID: 24373966.
75. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.  Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K. Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934.
76. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes . Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M, Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J.  JCO. 2013 Oct 1;31(28):3557-64. PMID: 24002510.
77. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia . Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK.  Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763.
78. Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells . Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y.  Gut 2013 Sep 2. PMID: 24000294.
    
79. High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells. Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K, *Co-Corresponding.  Genes Chromosome Cancer. 2013 Oct 3. PMID: 24123713.
80. Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors . Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC. JBC. 2013 Aug 16;288(33):23814-22 PMID: 23814052.
81. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer . Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A.  Nucleic Acid Res. 2013  Sep;41(16):e157 PMID: 23861445.
82. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment . Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U.  Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689.
83. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.  Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. Blood. 2013, Apr 11;121(15):2875-81. PMID: 23390194.
84. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis . Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A.  JBC. 2013 Mar 29;288(13):8805-14. PMID: 23306203.
    
85. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis . Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S,* Co-Corresponding.  Journal of Immunology. 2013 Mar 15;190(6):2966-75. PMID: 23408834.
86. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma . Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ*, Co-Corresponding.  Gastroenterology. 2013 May;144(5):956-966. PMID: 23333711.
87. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms . Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A.  Cancer Res. 2012 Dec 27. PMID: 23066032.
88. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations . Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,  Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A.  Blood. 2012; 120(10):2076-86. PMID: 22753872.
89. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.  Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Leukemia. 2012 Sep 11. PMID: 23032694.
90. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.  Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552.
91. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis . Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315.
92. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation . Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.  Blood. 2012 May 24. PMID: 22627766.
93. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia . Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A.  Leuk Lymphoma. 2012 Apr 18.  PMID: 22448921.
94. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes . Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.  Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540.
95. Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis . Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC.  J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535.
96. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q . Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A.   J Biol Chem. 2011 Apr 30. PMID: 21532034.
97. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis . Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A. PLOS Genetics. 2011 Mar;7(3) PMID: 21483804.
98. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,  G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma. Cancer Research. 2011 Feb 1;71(3):955-63.PMID: 21189329.
99. Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis . Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC. J Biol Chem. 2011 Feb 25;286(8):6017-26.PMID: 21149447.
100. Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling . Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC.  J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.
101. Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia . Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B. Leuk Lymphoma. 2010 Jun;51(6):1108-14. PMID: 20536349.
102. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis . Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP.  Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039.
103. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells . Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J.  Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779.
104. Cytosine methylation dysregulation in neonates following intrauterine growth restriction . Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A.PLoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273.
105. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers . Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M.  Nucleic Acids Res. 2009 Jul;37(12):3829-39. PMID: 19386619.
106. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration . Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A.  PLOS One 2008 Aug 13;3(8):e2965   PMID: 18698424.
107. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS . Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,  Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A. Blood. 2008 Oct 15;112(8):3434-43  PMID: 18474728.
108. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A.  Leukemia and Lymphoma 2008 Oct;49(10):1963-75. PMID: 18949619.
109. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure . Zhou L, Opalinska J, Verma A. Cell Cycle. 2007, 1;6(5):534. PMID:17351344.
110. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors . Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A. Blood. 2006, 15;108(13):4170-7. PMID: 16940419.
111. Cytokine targets in the treatment of myelodysplastic syndromes . Verma A, and List A. Current Hematology Reports. 2005 Nov;4(6):429-35. PMID: 16232378.
112. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha . Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN. Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8.  PMID: 14597717.
113. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir . Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K. Bone Marrow Transplant. 2003 May;31(9):813-6.  PMID: 12732890.
114. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide . Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L..  Journal of Biological Chemistry. 22;277(47):44988-95.  PMID: 12239215.
115. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia . Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L.. Journal of Immunology. 2002 Jun 15;168(12):5984-8. PMID: 12055203.
116. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis.  Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC.  Journal of Biological Chemistry. 2002, 277(10):7726-35. PMID: 11773065.
117. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia . Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K. Blood  2002, 99(6):2255-8.  PMID: 1877308

Review articles

1. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A, “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.” Leukemia. 2016 Mar;30(3):536-44. PMID: 26500138.
2. Role of DNA methylation in renal cell carcinoma. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A. J Hematol Oncol. 2015 Jul 22;8(1):88. PMID: 26198328.
3. A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Verma A, Steidl U. Nat Med. 2015;21:113-4. PMID: 25654599
4. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G.  Leukemia. 2015 Jul;29(7):1458-69. PMID: 25761935.
5. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y.  Blood. 2014 Aug 7;124(6):873-81. PMID: 24923296.
6. Retinoic acid signaling pathways in development and diseases.  Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK, Evans T.  Bioorg Med Chem. 2014 Jan 15;22(2):673-83. PMID: 24393720.
7. Stem cell origin of myelodysplastic syndromes. Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*,  Steidl U* *CoCorresponding. Oncogene. 2013 Dec 16. PMID: 24336326.
8. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Pathak S, Roth M, Verma A*, Steidl U*. *CoCorresponding.  Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. PMID: 24215532.
9. Linked-in: design and efficacy of antibody drug conjugates in oncology. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK.  Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630.
10. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Khan H, Vale C, Bhagat T, Verma A.   Semin Hematol. 2013 Jan;50(1):16-37. PMID: 23507481.
11. Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia. Elias H, Verma A. Leuk Lymphoma. 2012 Dec;53(12):2337-8. PMID: 22897726.
12. Alterations in the ribosomal machinery in cancer and hematologic disorders. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A.  J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827.
13. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A.  Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291.
14. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Sharma A, Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A. WIREs Systems Biology and Medicine. 2010 Nov-Dec;2(6):654-69. PMID: 20890963.
15. Aberrant DNA methylation in malignant melanoma. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A.  Melanoma Research. 2010, Aug; 20(4):253-65 PMID: 20418788.
16. Mechanism of action of lenalidomide in hematological malignancies. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A.J Hematol Oncol. 2009 Aug 12;2:36. PMID: 19674465. 
17. A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL. Opalinska J, Zhou L, Verma A.  Leukemia Research (Commentary) 2007 Mar;48(3):443-4.  PMID: 17454578.
18. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A. Journal of Interferon and Cytokine Research 2007, 27(7):543. PMID: 17651015.
19. Engineered antibodies act as targeted therapies in cancer treatment. Mohindru M, Verma A. Indian Journal of Pediatrics, 2005 Nov;72(11):943-7. PMID: 16391449.
20. Mitogen-activated protein kinase pathways in interferon signaling. Sassano A, Verma A, Platanias LC. Methods Molecular Medicine, 2005;116:135-50. PMID: 16000859.
21. Kinase inhibitors translate lab discoveries into exciting new cures for cancers. Mohindru M, Verma A.  Indian Journal of Pediatrics, 2004 Aug;71(8):713-8. PMID: 15345872.
22. Jak family of kinases in cancer. Verma A, Kambhampati S, Parmar S, Platanias LC. Cancer Metastasis Rev. 2003 Dec;22(4):423-34. PMID: 12884916.
23. Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. Verma A, and Platanias LC. Leukemia and Lymphoma.  2002, 44:703-709. PMID: 12153154.
24. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Verma A, and Stock W. Current Opinion in Oncology. 2001, 13:14-20. PMID: 11148680.